Transthyretin amyloid cardiomyopathy, also known as ATTR-CM in short, is a heart muscle disorder that often goes undetected and can be life-threatening. In ATTR-CM, a protein called transthyretin, typically found in the bloodstream, becomes abnormal in shape and accumulates in the heart, nerves, and other organs. Worldwide, there are an estimated 300,000 - 500,000 patients with ATTR-CM. Pfizer's Vyndaqel and Vyndamax capsules are the FDA-approved treatments for ATTR-CM.
The stock we are bringing to your attention today is that of BridgeBio Pharma Inc. (BBIO) whose investigational drug for the treatment of transthyretin amyloid cardiomyopathy is at the FDA altar, awaiting a decision.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.